PA
LXRX icon

Parallel Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Parallel Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$593 Hold
247
– – ﹤0.01% 3769
2026
Q1 		$385 Buy
+247
New +$359 ﹤0.01% 3714
2018
Q1 		– Sell
-198
Closed -$2K – 2136
2017
Q4 		$2K Buy
+198
New +$2.06K ﹤0.01% 1861

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Parallel Advisors's LXRX Position: Q2 2026 in Review

Parallel Advisors held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 247 shares worth $593. The position accounts for ﹤0.01% of the portfolio, ranked #3769.

Parallel Advisors first reported a position in LXRX in Q4 2017 and has held it in 3 quarters since. The position peaked at $2K in Q4 2017. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Parallel Advisors held 247 shares of Lexicon Pharmaceuticals worth $593 as of Q2 2026.
  • Parallel Advisors left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3769 holding.
  • Parallel Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2017 and has held it in 3 quarters since.
  • Parallel Advisors's Lexicon Pharmaceuticals position peaked at $2K in Q4 2017.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.